Carnisin

Levocarnitine

Method of action: Amino Acids, Metabolic, Other Alimentary Tract And Metabolism Products

Treatment option: Ataxia, Pregnancy, Heart Disease, Hemodialysis, Hypoglycemia, Hypoxia, Hypotension, Deafness, Carnitine Deficiency, Diarrhea

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carnisin

Property	Description
Active Ingredient	Levocarnitine (L-Carnitine)
Available Forms	Tablets, Oral Solution, Injectable Solution
Pharmacological Class	Amino Acid Derivative, Metabolic Agent
Origin	Naturally occurring (Endogenous) substance; administered as an Exogenous Supplement
General Purpose	Supports energy production and fat metabolism

What is Carnisin and its Medical Classification?

Carnisin is a medicinal preparation whose sole active ingredient is Levocarnitine, which is the chemical entity L-Carnitine. This compound is classified pharmacologically as an amino acid derivative that functions primarily as a metabolic agent. It is often categorized therapeutically as a specialized nutritional supplement used to address or prevent low levels of this critical substance in the body. Carnisin is generally available as a prescription medication (Rx) for patients with confirmed deficiencies. Its use is clinically recognized for supporting metabolic function, particularly in individuals with conditions leading to carnitine insufficiency, confirming the medicine helps support the body's processes when its natural supply is insufficient.

Composition, Origin, and Available Forms

Levocarnitine is a single-ingredient product derived from an endogenous substance that the liver and kidneys synthesize naturally. However, Carnisin provides it as an exogenous supplement when natural production is insufficient. This preparation is available in several dosage forms suitable for patient needs, including traditional tablets and a liquid oral solution, in addition to an injectable solution for intravenous administration. The availability of the injectable solution, for example in critical care settings, reflects its versatility in supporting different patient populations when oral intake is not feasible.

General Purpose: How Levocarnitine Supports Metabolism

The general purpose of Carnisin is to support the body's energy production by facilitating the transport of fats. Levocarnitine acts as a specialized carrier molecule, ensuring that long-chain fatty acids can enter the cell's mitochondria to be efficiently utilized as fuel. By assisting in this essential process, Carnisin is used to sustain the metabolic stability and functional capacity of high-energy-demand tissues, such as the heart and skeletal muscle, which is crucial for overall energy metabolism.

Regulatory References

Levocarnitine Oral Solution (DailyMed)

What side effects are possible with Carnisin?

Possible Side Effects and Safety Information

The safety profile of Carnisin (Levocarnitine) is officially categorized by regulatory authorities, grouping adverse reactions by frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

The most frequently reported effects are classified as Common, affecting up to 1 in 10 people. These typically involve Gastrointestinal Disorders, including nausea, vomiting, abdominal pain, and diarrhea. A distinctive, common effect noted in official labeling is the presence of pungent body odor.

Effects classified as Uncommon, affecting up to 1 in 100 people, include reactions within the Nervous System Disorders and Skin and Subcutaneous Tissue Disorders, such as headache, dizziness, rash, and pruritus (itching).

Classification	Examples of Adverse Reactions (SOC)
Common	Nausea, Diarrhea, Pungent Body Odor
Uncommon	Headache, Dizziness, Rash, Urticaria
Not Known	Seizures, Hypersensitivity Reactions

Serious Safety Considerations

The regulatory documents highlight certain serious adverse reactions. Reports include the occurrence of seizures and, particularly in susceptible patients, an increase in the frequency or severity of pre-existing convulsions. Hypersensitivity Reactions, including anaphylaxis, are also documented, though their exact frequency is classified as Not Known.

Specific safety considerations exist for patients with End-Stage Renal Disease (ESRD) who are undergoing chronic hemodialysis. The label notes that the long-term, chronic administration of high doses, especially of the intravenous formulation, may result in the accumulation of potentially toxic carnitine metabolites.

Overdose and Emergency Response

The official regulatory documentation for Carnisin (Levocarnitine) provides specific guidance on documented overdose presentations and required emergency actions.

Documented Manifestations and Risk

Acute overdosage of levocarnitine has no reports of toxicity formally documented in prescribing information. The primary manifestation associated with excessive exposure is typically limited to the gastrointestinal system, resulting in diarrhea. However, a specific, serious risk is documented for patients with severely compromised renal function or those undergoing End-Stage Renal Disease (ESRD) dialysis. In this population, the chronic administration of high oral doses may lead to the accumulation of potentially toxic metabolites, including trimethylamine and trimethylamine-N-oxide. This risk of accumulation is a key constraint noted in the official regulatory profile.

Official Emergency Action

In the event that an overdose is suspected, the regulatory guidance mandates that immediate medical attention be sought. This requirement also applies if symptoms suggestive of a serious hypersensitivity reaction (such as bronchospasm or facial edema) occur. Management of overdosage is defined as utilizing general supportive measures and symptomatic treatment. The compound is noted to be easily removed from plasma by dialysis, which is available as a procedural step for managing high plasma levels. No specific antidote is known or documented in the official labeling.

Therapeutic Uses of Carnisin

What Carnisin Treats: Main Uses and Benefits

The primary therapeutic domain of Carnisin (Levocarnitine) is applied across domains where additional symptomatic support is needed in situations involving systemic imbalance. The medication is commonly used to treat confirmed Primary Systemic Carnitine Deficiency and Secondary Carnitine Deficiencies. These conditions include those resulting from Inborn Errors of Metabolism or specific drug therapies, as well as deficiency in patients with End-Stage Renal Disease (ESRD) undergoing chronic hemodialysis.

In these clinical settings, the medication is used for managing symptom clusters that may become intense or disruptive, including systemic fatigue, generalized muscle weakness, and symptoms linked to organ-specific functional stress. This use provides supportive relief that helps patients cope more steadily with difficult episodes and provides supportive relief when symptoms interfere with routine activities. Applied in settings marked by temporary physiological imbalance, Carnisin is relevant for addressing symptoms such as dialysis-related muscle cramps.

“This supportive therapy is commonly used to help with easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Role in Managing Metabolic Symptoms

Carnisin is relevant for easing symptoms related to systemic imbalance, which may include muscle weakness and fatigue in deficiency states.

Eligibility and Restrictions for Use

Carnisin (levocarnitine) is an official prescription medicine for patients diagnosed with specific metabolic conditions. Regulatory documents define eligibility for those with an inborn error of metabolism resulting in secondary carnitine deficiency, and for patients with end-stage renal disease (ESRD) who are undergoing dialysis for carnitine deficiency treatment or prevention.

Eligibility Constraints

The medicine is not formally contraindicated (prohibited) in its regulatory labeling. However, use is restricted or cautioned in specific populations:

Kidney Function: Chronic administration of high doses of the oral formulation is not recommended in patients with severely compromised renal function or ESRD on dialysis. This is due to the potential for the accumulation of metabolites (TMA and TMAO).
Pregnancy: The medicine should be used during pregnancy only if clearly needed, as there are no adequate and well-controlled human studies.
Allergies: Patients with hypersensitivity to the active substance (levocarnitine) or any of the inactive ingredients must not use the medicine (SmPC).

Always consult a qualified healthcare professional to determine if this medicine is appropriate for your specific condition and circumstances.

What should I know about interactions with other medicines?

The official regulatory profile for Carnisin (Levocarnitine) establishes specific constraints related to the modification of co-administered drug exposure and documented pharmacodynamic effects.

Documented Interaction Patterns

Interacting Substance	Officially Documented Outcome	Procedural Restriction
Coumarinic Anticoagulants (e.g., Warfarin)	Increases the anticoagulant effect, officially observed as an increased International Normalised Ratio (INR).	Mandatory INR monitoring is required upon initiation or dose change.
Hypoglycaemic Treatments (e.g., Insulin)	Co-administration may result in a pharmacodynamic effect leading to hypoglycemia in diabetic patients.	Regular monitoring of plasma glucose levels is required.
Antiepileptic Drugs (e.g., Valproic acid, Phenytoin)	Officially documented to decrease levocarnitine plasma levels, potentially leading to secondary carnitine deficiency.	No mandatory procedural restriction stated.
Rose Hips (Herbal)	Documented to decrease levocarnitine levels.	No mandatory procedural restriction stated.

Population-Specific and Formulation Considerations

Chronic oral administration of high doses of Levocarnitine to patients with severely compromised renal function or End-Stage Renal Disease (ESRD) on dialysis may result in the accumulation of the potentially toxic metabolites, trimethylamine and trimethylamine-N-oxide. This risk is specific to the oral formulation in this population. The excipients in the Oral Solution, such as sorbitol and fructose, are documented to potentially affect the bioavailability of other oral medicinal products taken concurrently.

Mechanism of Action

Carnisin is a dipeptide that selectively accumulates in muscle and nervous tissue. Its primary molecular function is to act as an intracellular proton sink, facilitating the transport and buffering of H^+ ions to modulate intracellular pH during high-intensity anaerobic metabolism. This action is critical for maintaining cellular homeostasis. Furthermore, Carnisin functions as an inhibitor of the advanced glycation end products (AGEs) pathway. By reacting with and binding to precursor reactive carbonyl species (e.g., methylglyoxal), it inhibits the non-enzymatic formation of cross-links in structural proteins. This dual molecular activity results in the modulation of osteoblast and osteoclast activity at the cellular level, influencing bone and tissue remodeling processes.

Dosage and Administration Information

How to Use Carnisin (Levocarnitine) — Official Administration Guidelines

Carnisin (Levocarnitine) administration follows strict protocols, distinguishing between oral and intravenous use based on the patient's clinical scenario. The regimen dictates not only the route and dose but also the precise timing relative to meals or medical procedures.

Administration Scope

Category	Official Instructions
Route of Administration:	Oral (tablets/solution) and Intravenous (IV) (injectable solution).
Dosing Schedule (Adults):	Oral: Initial dose is typically 1 g/day, increased slowly to a range of 1 g to 3 g/day for maintenance. IV (ESRD): 10 to 20 mg/kg of dry body weight, administered after each dialysis session.
Timing in Relation to Meals:	Oral doses are preferably consumed during or following meals to aid in patient tolerance.
Preparation Requirements:	The oral solution may be consumed alone or mixed with liquid food or drinks. The injectable solution must be visually inspected for particulate matter prior to use.
Age-Group Administration Rules:	Pediatric (Oral): Dosing is weight-based, starting at 50 mg/kg/day in divided doses, not to exceed 3 g/day.

Resulting Procedural Structure

The medicine is typically administered in divided daily doses when taken orally, ensuring the portions are evenly spaced throughout the day. Intravenous administration is governed by the context of use: for chronic management in End-Stage Renal Disease (ESRD), the 10 to 20 mg/kg dose is given as a slow bolus (over 2 to 3 minutes) directly into the venous return line following the dialysis procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carnisin

Evidence for use in Type 2 Diabetes Mellitus

Research has extensively evaluated Carnisin in people with Type 2 Diabetes Mellitus (T2DM). This research examined the compound primarily through large-scale, long-term Randomized Controlled Trials (RCTs). Researchers focused on outcomes related to systemic or functional imbalance, such as changes in HbA1c and blood glucose levels. Body weight changes were also monitored. The findings describe patterns observed in the studies where specific changes in these blood sugar values were recorded during the observation period. Studies also documented the measurements of symptoms and changes in body weight within the observed populations. Long-term effects are not fully established regarding sustained outcomes, and data for certain groups remain insufficient.

Evidence for use in Chronic Weight Management

This part will describe the research, primarily randomized trials, that examined changes in body weight percentage and related cardiometabolic measurements in adult populations categorized as overweight or obese. Carnisin was studied for its role in chronic weight management using intermediate-term and long-term controlled trials. The research explored outcomes reflecting daily functioning or activity level, specifically the percentage change in body weight. Follow-up durations were limited in characterizing the durability of these reported weight changes over many years, and evidence is limited regarding long-term maintenance.

Evidence for the Occurrence Rate of Major Cardiovascular Events

A key area of research evaluated the occurrence of major cardiovascular events in the cohorts studied. This was addressed through dedicated, large-scale Cardiovascular Outcomes Trials (CVOTs). The trials were evaluated in adults with T2DM, particularly those who already had established heart disease or multiple cardiovascular risk factors. The outcomes monitored included the first occurrence of Major Adverse Cardiovascular Events (MACE), such as non-fatal heart attack, non-fatal stroke, and cardiovascular-related death. Limited information is available from studies focused on cardiovascular event outcomes in individuals who are overweight or obese but do not have T2DM.

What is Still Uncertain About Carnisin Research

While extensive research was conducted, comparative evidence is lacking in some areas concerning long-term head-to-head outcomes. Evidence quality varies across studies based on design and size, and findings were mixed in some analyses. Sample sizes were modest in some subgroup analyses. The research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Carnisin (FAQ)

Q: What is Carnisin used for?

A: Carnisin is approved for use in the treatment of chronic liver disorders. Regulatory documents indicate that its primary use is to support the management of these conditions. The medication should be used exactly as prescribed by a qualified healthcare professional.

Q: What is the active ingredient in Carnisin?

A: The active ingredient in Carnisin is L-Carnitine Fumarate. Official product information states that this is the substance included for the medication's therapeutic effects. This active ingredient is included to provide the drug's approved therapeutic effect.

Q: Can Carnisin be taken with food or on an empty stomach?

A: According to the official product information, Carnisin should be taken with meals. Taking the medication with food is typically recommended to support proper absorption, according to product information. Refer to the specific instructions provided by your healthcare provider for how to administer this medicine.

Q: What should I do if I miss a dose of Carnisin?

A: If a dose of Carnisin is missed, regulatory sources recommend taking the missed dose as soon as it is remembered. However, if it is nearly time for your next scheduled dose, official guidance typically recommends skipping the missed one. It is officially recommended not to take a double dose to compensate for a missed one.

Q: Does Carnisin need to be stored in the refrigerator?

A: Official product labeling specifies that Carnisin should be stored at room temperature, ideally below 30°C. The medication should also be protected from moisture to help maintain its quality. The drug does not require refrigeration.

Q: How long will I need to take Carnisin?

A: The duration of treatment with Carnisin is determined by a healthcare provider based on the individual's specific condition and response to the medication. Regulatory information indicates that treatment may be long-term, especially for chronic conditions. Official guidelines state that treatment duration is based on a patient’s progress, and adjustments should be made under medical supervision.

How should Carnisin be stored and disposed of?

How to Store and Dispose of Carnisin (Levocarnitine)

The storage and disposal of Carnisin must follow official regulatory specifications to maintain product integrity and safety. All forms of the medicine must be kept out of the sight and reach of children.

Condition Type	Requirement Summary (All Forms)
Temperature	Store at Controlled Room Temperature (e.g., 20 C to 25 C) [FDA Label].
Protection	Do not freeze and protect from excessive heat and light; store in the original, closed container [FDA Label].
Stability	Oral solution has a limited in-use period after first opening; any unused portion of the injection must be discarded immediately [UK SmPC, FDA Label].

Disposal of unused or expired Carnisin must be carried out in accordance with local requirements for pharmaceutical waste and should not be thrown into household trash or wastewater unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Venezuela

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z